Xanthomicrol: Effective therapy for cancer treatment

Poormolaie, Neda; Mohammadi, Mohammad Reza; Mir, Amirabbas; Asadi, Mehrdad; Kararoudi, Alireza Nouhi; Vahedian, Vahid; Maroufi, Nazila Fathi; Rashidi, Mohsen

doi:10.1016/j.toxrep.2023.02.008

Cited by 6 publications

(5 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the effect of EUP and XAN on apoptosis induction was assessed by staining A375 melanoma cells with NucView 488, a substrate of the enzyme caspase-3, able to detect caspase-3/7 activity inside cells [ 45 ]. Previous studies demonstrated the capacity of EUP [ 13 , 18 , 24 ] and XAN [ 9 , 14 , 27 , 30 ] to induce apoptosis in various cancer cell lines. The 24 h-treatment of melanoma A375 cells with XAN induced a noticeable increase in the number of green-fluorescent cells in comparison to control cells at both tested concentrations, whereas EUP induced a significant increase in the number of rounded/green-fluorescent apoptotic cells at 25 μM.…”

Section: Discussionmentioning

confidence: 99%

“…This methoxylated flavone is a bioactive compound present in several plants and herbs with a long application in traditional medicine, such as Varthemia iphionoides , Achillea erba-rotta subsp. moschata (Wulfen) I. Richardson, Clinopodium douglasii , Dracocephalum kotschyi Boiss, Baccharis pentlandii D.C., Baccharis densiflora Wedd, Ocimum gratissimum L., and Artemisia campestris L. [ 9 , 14 , 27 , 28 , 29 , 30 ]. XAN has antioxidant [ 9 ], antimicrobial [ 9 ], anti-inflammatory [ 9 ], and anticancer properties [ 9 , 14 , 27 , 28 , 29 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

“…moschata (Wulfen) I. Richardson, Clinopodium douglasii , Dracocephalum kotschyi Boiss, Baccharis pentlandii D.C., Baccharis densiflora Wedd, Ocimum gratissimum L., and Artemisia campestris L. [ 9 , 14 , 27 , 28 , 29 , 30 ]. XAN has antioxidant [ 9 ], antimicrobial [ 9 ], anti-inflammatory [ 9 ], and anticancer properties [ 9 , 14 , 27 , 28 , 29 , 30 ]. The XAN antitumor properties are linked to its capacity to inhibit the proliferation and viability in cancer cells [ 9 , 14 , 27 , 28 , 29 ], angiogenesis [ 27 ], cancer-related enzymes [ 27 , 30 ], and to induce apoptosis [ 9 , 14 , 27 , 30 ] and cell cycle arrest [ 9 , 14 , 27 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

“…XAN has antioxidant [ 9 ], antimicrobial [ 9 ], anti-inflammatory [ 9 ], and anticancer properties [ 9 , 14 , 27 , 28 , 29 , 30 ]. The XAN antitumor properties are linked to its capacity to inhibit the proliferation and viability in cancer cells [ 9 , 14 , 27 , 28 , 29 ], angiogenesis [ 27 ], cancer-related enzymes [ 27 , 30 ], and to induce apoptosis [ 9 , 14 , 27 , 30 ] and cell cycle arrest [ 9 , 14 , 27 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparative Evaluation of Anticancer Activity of Natural Methoxylated Flavones Xanthomicrol and Eupatilin in A375 Skin Melanoma Cells

Rosa,

Piras,

Pollastro

et al. 2024

Life

View full text Add to dashboard Cite

Melanoma is a skin cancer caused by the malignant transformation of melanocytes and cutaneous melanoma represents the most aggressive and deadliest type of skin cancer with an increasing incidence worldwide. The main purpose of the present research was to evaluate the anticancer effects of the natural bioactive compounds xanthomicrol (XAN) and eupatilin (EUP) in human A375 malignant skin melanoma cells, a cell line widely used as an in vitro model of cutaneous melanoma. XAN and EUP are lipophilic methoxylated flavones with antioxidant, anti-inflammatory, and antitumor properties. The effects of XAN and EUP on cell viability, morphology, lipid profile, oxidative status, apoptosis, and mitochondrial membrane polarization were determined and compared in A375 cells. At 24 h-incubation (MTT assay), XAN significantly reduced viability at the dose range of 2.5–200 μM, while EUP showed a significant cytotoxicity from 25 μM. Moreover, both methoxylated flavones induced (at 10 and 25 μM, 24 h-incubation) marked cell morphological alterations (presence of rounded and multi-nucleated cells), signs of apoptosis (NucView 488 assay), and a noteworthy mitochondrial membrane depolarization (MitoView 633 assay), coupled to a marked lipid profile modulation, including variations in the ratio of phospholipid/cholesterol and a decrease in the oleic, palmitic, and palmitoleic acid amounts. Moreover, a remarkable time-dependent ROS generation (2′,7′-dichlorodihydrofluorescein diacetate assay) was observed during 3 h-incubation of A375 cancer cells in the presence of XAN and EUP (10 and 25 μM). Our results confirm the potential antitumor effect of natural EUP and XAN in cutaneous melanoma by the activation of multiple anticancer mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparative Evaluation of Anticancer Activity of Natural Methoxylated Flavones Xanthomicrol and Eupatilin in A375 Skin Melanoma Cells

Rosa,

Piras,

Pollastro

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

“…5,7-dihydroxy-3,6,8-trimethoxyflavone (flavone A) has been reported as plant-derived isomeric flavonoids, which induces apoptosis in highly tumorigenic cancers [ 109 ]. In addition, 40 μM flavone treatment for 9 h induced maximum apoptosis in MIA Paca-2 cell lines through intrinsic pathways, includes extracellular signal-regulated kinase (ERK), pS6, and Bcl-2 associated death promoter (BAD) proteins [ 109 , 110 ]. Hence, flavone A may be employed as a natural therapeutic molecule for treating pancreatic cancer.…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

Therapeutic Approaches in Pancreatic Cancer: Recent Updates

Kumar

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Cancer is a significant challenge for effective treatment due to its complex mechanism, different progressing stages, and lack of adequate procedures for screening and identification. Pancreatic cancer is typically identified in its advanced progression phase with a low survival of ~5 years. Among cancers, pancreatic cancer is also considered a high mortality-causing casualty over other accidental or disease-based mortality, and it is ranked seventh among all mortality-associated cancers globally. Henceforth, developing diagnostic procedures for its early detection, understanding pancreatic cancer-linked mechanisms, and various therapeutic strategies are crucial. This review describes the recent development in pancreatic cancer progression, mechanisms, and therapeutic approaches, including molecular techniques and biomedicines for effectively treating cancer.

show abstract